Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Ferring Pharmaceuticals
Ferring Presents Early Response Data From Pivotal Phase 3 Trial for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASPN 2024
July 15, 2024
From
Ferring Pharmaceuticals
Via
Business Wire
Ferring to Present New Data Analyses at ASPN 2024 for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
June 24, 2024
From
Ferring Pharmaceuticals
Via
Business Wire
Ferring Pharmaceuticals and Posterity Health Launch New Partnership to Activate Men About Their Fertility
June 20, 2024
From
Ferring Pharmaceuticals
Via
Business Wire
Final Five-Year Analysis of Phase 3 Data With ADSTILADRIN® (nadofaragene firadenovec-vncg) Shows Durable Bladder Preservation and Consistent Long-Term Safety in BCG-unresponsive NMIBC
May 06, 2024
From
Ferring Pharmaceuticals
Via
Business Wire
Ferring Pharmaceuticals and SK Pharmteco Enter into Commercial Gene Therapy Manufacturing Deal
April 18, 2024
From
Ferring Pharmaceuticals
Via
Business Wire
Ferring Adds Three New Studies to Non-Muscle Invasive Bladder Cancer Clinical Trial Program With ADSTILADRIN® (nadofaragene firadenovec-vncg)
April 16, 2024
From
Ferring Pharmaceuticals
Via
Business Wire
Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring
April 09, 2024
From
Ferring Pharmaceuticals
Via
Business Wire
Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024
April 08, 2024
From
Ferring Pharmaceuticals
Via
Business Wire
Three-Year Follow-up Data in BCG-Unresponsive NMIBC Show Durable Response to Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Two Patient Cohorts
April 08, 2024
From
Ferring Pharmaceuticals
Via
Business Wire
Phase 4 Study Evaluating Use of ADSTILADRIN® (nadofaragene firadenovec-vncg) in Real-World Setting
January 24, 2024
From
Ferring Pharmaceuticals
Via
Business Wire
Ferring Announces Full Availability of ADSTILADRIN® (nadofaragene firadenovec-vncg) in the U.S.
January 16, 2024
From
Ferring Pharmaceuticals
Via
Business Wire
Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement
December 11, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
New Data Show Durable Response Following Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg)
November 29, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
ACG 2023 Presentations for REBYOTA® (fecal microbiota, live – jslm) Explore Association Between Gut Microbiome Composition and Health-Related Quality of Life and Evaluate Efficacy and Safety in Older Patients With Comorbidities
October 23, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
More Real-World Data and New Analyses of Data for REBYOTA® (fecal microbiota, live – jslm) Presented at IDWeek 2023
October 11, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
Ferring to Present New Data Analyses at ACG 2023 for REBYOTA® (fecal microbiota, live – jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection
October 03, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
Ferring to Present New Data Analyses at IDWeek 2023 for REBYOTA® (fecal microbiota, live – jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection
September 21, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
First Bladder Cancer Patient Dosed with Commercially Available Intravesical Gene Therapy ADSTILADRIN® (nadofaragene firadenovec-vncg)
September 12, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
August 24, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
Tickers
RPRX
Largest Integrated Safety Analysis From Five Prospective Clinical Trials for REBYOTA® (fecal microbiota, live – jslm) Published in Therapeutic Advances in Gastroenterology
July 11, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
Ferring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors
June 22, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
Ferring Pharmaceuticals successfully increases its second Swiss Franc Bond offering by CHF 80 million
June 16, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
Ferring Pharmaceuticals Receives U.S. FDA Approval of Drug Substance Manufacturing Scale-up Process for Gene Therapy ADSTILADRIN® (nadofaragene firadenovec-vncg)
June 12, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
Ferring Announces Positive Topline Phase 3 Results for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
May 26, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023
May 08, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
Retrospective Analysis of Data Evaluating Safety and Efficacy of REBYOTA™ (fecal microbiota, live – jslm) in a Real-World Patient Population with Comorbidities and Risk Factors Published in Open Forum Infectious Diseases
May 04, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
Ferring to Present Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, at DDW 2023
April 18, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health
April 18, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
Ferring Announces Abstract of the First Prospective, Multi-National, Real-world Study of Rekovelle® (follitropin delta) at the Congress of the Pacific Society for Reproductive Medicine
March 13, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
Ferring Pharmaceuticals Announces Availability of REBYOTA™ (fecal microbiota, live – jslm) – the First and Only FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrence of C. diff Infection in Adults
February 14, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.